




RealRate

PHARMACEUTICAL 2019

Zynerba Pharmaceuticals Inc
Rank 116 of 361



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Zynerba Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zynerba Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 105% points. The greatest weakness of Zynerba Pharmaceuticals Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 317%, being 68% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	66,955
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,726
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	487
Other Revenues	86
Property and Equipment	372
Research and Development	27,245
Selling, General and Administrative Expense	13,239

Output Variable	Value in 1000 USD
Assets	67,327
Liabilities	9,726
Expenses	40,484
Revenues	86
Stockholders Equity	57,602
Net Income	-39,911
Comprehensive Net Income	-39,911
BaseVar	59,055
ECR before Limited Liability	222%
Economic Capital Ratio	317%